

# CITATION REPORT

List of articles citing

**Non-vitamin-K oral anticoagulants and laboratory testing: now and in the future: Views from a workshop at the European Medicines Agency (EMA)**

**DOI: 10.1093/ehjcvp/pvw032**

**European Heart Journal - Cardiovascular Pharmacotherapy, 2017, 3, 42-47.**

**Source:** <https://exaly.com/paper-pdf/66754092/citation-report.pdf>

**Version:** 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
42	Emerging therapeutic uses of direct-acting oral anticoagulants: An evidence-based perspective. <i>Pharmacological Research</i> , <b>2017</b> , 120, 206-218	10.2	10
41	Rivaroxaban non-responders: do plasma measurements have a place?. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2017</b> , 56, e16-e18	5.9	2
40	Practical guidance on the use of laboratory testing in the management of bleeding in patients receiving direct oral anticoagulants. <i>Vascular Health and Risk Management</i> , <b>2017</b> , 13, 457-467	4.4	33
39	[Direct oral anticoagulants (DOACS): A necessary focus]. <i>JMV-Journal De Medecine Vasculaire</i> , <b>2018</b> , 43, 198-205	0.6	
38	Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease: systematic review and meta-analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , <b>2018</b> , 4, 111-118	6.4	23
37	Pharmacokinetic Interactions of Clinical Interest Between Direct Oral Anticoagulants and Antiepileptic Drugs. <i>Frontiers in Neurology</i> , <b>2018</b> , 9, 1067	4.1	43
36	Major bleeding with old and novel oral anticoagulants: How to manage it. Focus on general measures. <i>International Journal of Cardiology</i> , <b>2018</b> , 268, 80-84	3.2	3
35	Detecting clinically relevant rivaroxaban or dabigatran levels by routine coagulation tests or thromboelastography in a cohort of patients with atrial fibrillation. <i>Thrombosis Journal</i> , <b>2018</b> , 16, 3	5.6	29
34	Pharmacogenetics of anticoagulants used for stroke prevention in patients with atrial fibrillation. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2019</b> , 15, 449-458	5.5	5
33	Patients on NOACs in the Emergency Room. <i>Current Neurology and Neuroscience Reports</i> , <b>2019</b> , 19, 40	6.6	2
32	Cerebral Ischemia in Patients on Direct Oral Anticoagulants. <i>Stroke</i> , <b>2019</b> , 50, 873-879	6.7	27
31	NOACs in Anesthesiology. <i>Transfusion Medicine and Hemotherapy</i> , <b>2019</b> , 46, 282-293	4.2	2
30	The impact of the introduction of direct oral anticoagulants into a general practice and hospital anticoagulant services: two local service evaluations. <i>British Journal of Health Care Management</i> , <b>2019</b> , 25, 1-12	0.4	
29	Who approves/pays for additional monitoring?. <i>European Heart Journal Supplements</i> , <b>2019</b> , 21, M64-M67	1.5	2
28	Monitoring of biomarkers in heart failure. <i>European Heart Journal Supplements</i> , <b>2019</b> , 21, M5-M8	1.5	11
27	Pharmacokinetic and Pharmacodynamic Drug Monitoring of Direct-Acting Oral Anticoagulants: Where Do We Stand?. <i>Therapeutic Drug Monitoring</i> , <b>2019</b> , 41, 180-191	3.2	14
26	A Novel Whole Blood Point-of-Care Coagulometer to Measure the Effect of Direct Oral Anticoagulants and Heparins. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2019</b> , 45, 259-263	5.3	9

25	Differences between activities of coagulation factors after one month of therapy with different direct oral anticoagulant in pulmonary embolism patients. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2019</b> , 44, 236-242	2.2	1
24	Management in the Postanesthesia Care Unit of Complications in Cardiac Patients. <b>2019</b> , 510-525		
23	Response to the 'Breaking the rules for studies using real-world observational data: the case of direct-acting anticoagulants and antiepileptic drugs by Dr Brown et al.'. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , <b>2020</b> , 6, 157-158	6.4	
22	NOACs: an emerging class of oral anticoagulants-a review article. <i>Future Journal of Pharmaceutical Sciences</i> , <b>2020</b> , 6,	2.1	0
21	Point-of-Care Diagnostics in Coagulation Management. <i>Sensors</i> , <b>2020</b> , 20,	3.8	6
20	Ischemic stroke and dose adjustment of oral Factor Xa inhibitors in patients with atrial fibrillation. <i>Journal of Neurology</i> , <b>2020</b> , 267, 2007-2012	5.5	6
19	Pharmacogenetic-guided and clinical warfarin dosing algorithm assessments with bleeding outcomes risk-stratified by genetic and covariate subgroups. <i>International Journal of Cardiology</i> , <b>2020</b> , 317, 159-166	3.2	0
18	Relationship of Edoxaban Plasma Concentration and Blood Coagulation in Healthy Volunteers Using Standard Laboratory Tests and Viscoelastic Analysis. <i>Journal of Clinical Pharmacology</i> , <b>2021</b> , 61, 522-530	2.9	0
17	2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC)	9.5	1676
16	Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the 2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulants. <i>Thrombosis and Haemostasis</i> , <b>2021</b> , 121, 1008-1020 <sup>21</sup>	7	21
15	2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. <i>Europace</i> , <b>2021</b> , 23, 1612-1676	3.9	99
14	Guía ESC 2020 sobre el diagnóstico y tratamiento de la fibrilación auricular, desarrollada en colaboración de la European Association of Cardio-Thoracic Surgery (EACTS). <i>Revista Espanola De Cardiología</i> , <b>2021</b> , 74, 437.e1-437.e116	1.5	3
13	Treatment of direct oral anticoagulants in patients with liver cirrhosis and portal vein thrombosis. <i>Clinical and Molecular Hepatology</i> , <b>2021</b> , 27, 535-552	6.9	2
12	Evaluation of the in vitro stability of direct oral anticoagulants in blood samples under different storage conditions. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , <b>2021</b> , 81, 461-468	2	0
11	Oral anticoagulants: Interventional pharmaceutical study with reminder of good practices, and iatrogenic impact. <i>Annales Pharmaceutiques Francaises</i> , <b>2021</b> , 79, 409-417	1.3	
10	Pharmacokinetics of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Extreme Obesity. <i>Clinical Therapeutics</i> , <b>2021</b> , 43, e255-e263	3.5	2
9	2021 Korean Heart Rhythm Society Guidelines: Management of Atrial Fibrillation in Specific Clinical Settings. <i>Korean Journal of Medicine</i> , <b>2021</b> , 96, 264-295	0.5	
8	Antithrombotics today. <i>Vnitřni Lekarství</i> , <b>2018</b> , 64, 565-574	0.3	1

7	Use of New Oral Anticoagulants / Direct Oral Anticoagulants in Malignant Patients. <i>Cureus</i> , <b>2020</b> , 12, e7007	1.2	3
6	Determination of anticoagulant activity of direct oral anticoagulants: the current state of knowledge and a single center experience. <b>2017</b> , 53, 161-168		1
5	The Effect of Rivaroxaban on CYP4F2 and Transcription Factors Activity in HUVECs. <i>Applied Sciences (Switzerland)</i> , <b>2021</b> , 11, 10851	2.6	1
4	Different Oral Antithrombotic Therapy for the Treatment of Ventricular Thrombus: An Observational Study from 2010 to 2019. <i>International Journal of Clinical Practice</i> , <b>2022</b> , 2022, 1-12	2.9	1
3	Prospective cohort study on the use of low molecular weight heparin calibrated anti-Xa assay for measurement of direct oral Xa inhibitors in ex vivo patient samples.. <i>Pathology</i> , <b>2022</b> ,	1.6	0
2	Trough Concentration Deficiency of Rivaroxaban in Patients with Nonvalvular Atrial Fibrillation Leading to Thromboembolism Events. <b>2022</b> , Publish Ahead of Print,		0
1	Potential effects of anticoagulants in preclinical mice models of oral cancer: A systematic review.		0